The Role of Biosimilars in Inflammatory Bowel Disease.

Abstract

Monoclonal antibody biologic therapies, introduced nearly 20 years ago, revolutionized the treatment of inflammatory bowel disease (IBD) and are now well established as the most effective agents available. As the first of these biologic agents starts to come off patent, biosimilar agents have emerged as alternatives to originator drugs. The unique drug… (More)

Topics

6 Figures and Tables

Cite this paper

@article{Paramsothy2016TheRO, title={The Role of Biosimilars in Inflammatory Bowel Disease.}, author={Sudarshan Paramsothy and Noa Krugliak Cleveland and Nada Zmeter and David T Rubin}, journal={Gastroenterology & hepatology}, year={2016}, volume={12 12}, pages={741-751} }